Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H21NO2 |
Molecular Weight | 247.3327 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1(CCN(C)CC1)C2=CC=CC=C2
InChI
InChIKey=XADCESSVHJOZHK-UHFFFAOYSA-N
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
Molecular Formula | C15H21NO2 |
Molecular Weight | 247.3327 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html
Curator's Comment: description was created based on several sources, including:
http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html
Pethidine, also known as meperidine and Demerol, a narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Meperidine is an opioid agonist with multiple actions qualitatively similar to those of morphine. Most common adverse reactions were lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Pethidine can interact with muscle relaxants, some antidepressants, benzodiazepines, and ethanol.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21215785 |
450.1 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DEMEROL Approved UseFor the relief of moderate to severe pain. For preoperative medication. For support of anesthesia. For obstetrical analgesia. Launch Date-8.5656961E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
196 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.6 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
124 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2891328/ |
30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MEPERIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 g single, oral Overdose |
unknown, 17 years |
Other AEs: Myoclonus, Hyperreflexia... Other AEs: Myoclonus (1 patient) Sources: Hyperreflexia (1 patient) Respiratory depression (1 patient) Hypotension (1 patient) Tremor (1 patient) |
50 mg single, intrathecal Dose: 50 mg Route: intrathecal Route: single Dose: 50 mg Sources: |
unknown, 24 - 81 years Health Status: unknown Age Group: 24 - 81 years Sex: F Sources: |
Other AEs: Respiratory depression... |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: pain Age Group: 37 years Sex: M Population Size: 1 Sources: |
Disc. AE: Muscle twitching, Tremor... AEs leading to discontinuation/dose reduction: Muscle twitching (1 patient) Sources: Tremor (1 patient) |
600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years n = 7 Health Status: unknown Age Group: 44 years Sex: M+F Population Size: 7 Sources: |
Other AEs: Jitteriness, Hallucinations... Other AEs: Jitteriness (3 patients) Sources: Hallucinations (3 patients) Seizures (3 patients) |
50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Condition: pain Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Addiction, Respiratory depression... Other AEs: Addiction Sources: Respiratory depression (serious|grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperreflexia | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Hypotension | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Myoclonus | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Respiratory depression | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Tremor | 1 patient | 10 g single, oral Overdose |
unknown, 17 years |
Respiratory depression | 2 patients | 50 mg single, intrathecal Dose: 50 mg Route: intrathecal Route: single Dose: 50 mg Sources: |
unknown, 24 - 81 years Health Status: unknown Age Group: 24 - 81 years Sex: F Sources: |
Muscle twitching | 1 patient Disc. AE |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: pain Age Group: 37 years Sex: M Population Size: 1 Sources: |
Tremor | 1 patient Disc. AE |
1000 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 1000 mg, 1 times / day Route: intramuscular Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 37 years n = 1 Health Status: unhealthy Condition: pain Age Group: 37 years Sex: M Population Size: 1 Sources: |
Hallucinations | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years n = 7 Health Status: unknown Age Group: 44 years Sex: M+F Population Size: 7 Sources: |
Jitteriness | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years n = 7 Health Status: unknown Age Group: 44 years Sex: M+F Population Size: 7 Sources: |
Seizures | 3 patients | 600 mg 1 times / day multiple, intravenous Highest studied dose Dose: 600 mg, 1 times / day Route: intravenous Route: multiple Dose: 600 mg, 1 times / day Sources: |
unknown, 44 years n = 7 Health Status: unknown Age Group: 44 years Sex: M+F Population Size: 7 Sources: |
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Condition: pain Age Group: adult Sex: F Sources: |
|
Withdrawal syndrome neonatal | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Addiction | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, intramuscular Recommended Dose: 50 mg, 6 times / day Route: intramuscular Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Addiction | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, oral Recommended Dose: 50 mg, 6 times / day Route: oral Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Addiction | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 50 mg 6 times / day multiple, subcutaneous Recommended Dose: 50 mg, 6 times / day Route: subcutaneous Route: multiple Dose: 50 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Withdrawal syndrome neonatal | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Addiction | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | serious|grade 5 | 10 mg/mL multiple, intravenous Recommended Dose: 10 mg/mL Route: intravenous Route: multiple Dose: 10 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Page: 20.0 |
yes | likely (co-administration study) Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine Page: 20.0 |
||
Page: 20.0 |
yes | likely (co-administration study) Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine Page: 20.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388652/ Page: 5.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Meperidine (pethidine) outdated as analgesic in acute pancreatitis]. | 2000 Apr 1 |
|
Successful treatment of normeperidine neurotoxicity by hemodialysis. | 2000 Jan |
|
Pethidine reverses morphine-induced delirium. | 2000 Jun |
|
Urticaria induced by meperidine allergy. | 2000 Mar |
|
Sedation and analgesia for transvaginal oocyte retrieval: an audit resulting in a change of clinical practice. | 2001 |
|
Morphine, pethidine and buprenorphine disposition in the cat. | 2001 Dec |
|
[Comparison of vaginal misoprostol and oxytocin for labor induction in post-term pregnancy]. | 2001 Dec |
|
A randomized comparison of low-dose ketamine and lignocaine infiltration with ketamine-diazepam anaesthesia for post partum tubal ligation in Vanuatu. | 2001 Feb |
|
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. | 2001 Jan |
|
Randomized trial of needlescopic versus laparoscopic cholecystectomy. | 2001 Jan |
|
Remifentanil versus meperidine for monitored anesthesia care: a comparison study in older patients undergoing ambulatory colonoscopy. | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Opiate-sensitivity: clinical characteristics and the role of skin prick testing. | 2001 Jul |
|
Use of a new finger-mounted device to compare mechanical nociceptive thresholds in cats given pethidine or no medication after castration. | 2001 Jun |
|
Maternal analgesia during labor disturbs newborn behavior: effects on breastfeeding, temperature, and crying. | 2001 Mar |
|
Efficacy and safety of repeated postoperative administration of intramuscular diclofenac sodium in the treatment of post-cesarean section pain: a double-blind study. | 2001 Mar-Apr |
|
Upper and mid-ureteric stones: a prospective unrandomized comparison of retroperitoneoscopic and open ureterolithotomy. | 2001 Nov |
|
Patient-controlled pethidine after major upper abdominal surgery: comparison of the epidural and intravenous routes. | 2001 Nov |
|
Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital. | 2002 |
|
Use of opioid analgesics in a patient with chronic abdominal pain. | 2002 Apr |
|
Primary thoracoscopic evaluation of pleural effusion with local anesthesia: an alternative approach. | 2002 Apr-Jun |
|
Pulmonary function in infants exposed to pethidine. | 2002 Aug |
|
Selegiline: a second look. Six years later: too risky in Parkinson's disease. | 2002 Aug |
|
Upper gastrointestinal endoscopic ultrasound and its impact on patient management: 1990-2000. | 2002 Aug |
|
Nasal administration of opioids for pain management in adults. | 2002 Aug |
|
Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients. | 2002 Aug |
|
Intraperitoneal pethidine versus intramuscular pethidine for the relief of pain after laparoscopic cholecystectomy: randomized trial. | 2002 Dec |
|
Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies. | 2002 Jan 7 |
|
Mini cholecystectomy now a day stay surgery: anaesthetic management with multi modal analgesia. | 2002 Jul |
|
Double-blind, randomized trial comparing Harmonic Scalpel hemorrhoidectomy, bipolar scissors hemorrhoidectomy, and scissors excision: ligation technique. | 2002 Jun |
|
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions. | 2002 May |
|
Parenteral opioids for labor pain relief: a systematic review. | 2002 May |
|
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial. | 2002 May |
|
Next generation of everyday analgesics. | 2002 May-Jun |
|
Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic. | 2002 Oct |
|
[Long-memory of labor pain]. | 2002 Oct 14 |
|
Characterisation of silent and active genes for a variable large protein of Borrelia recurrentis. | 2002 Oct 14 |
|
Two in one: patient-controlled epidural analgesia (PCEA) to prevent erection and control pain in adult hypospadias-surgery patients. | 2002 Sep |
|
Can ketamine potentiate the analgesic effect of epidural morphine, preincisional or postincisional administration? | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/meperidine.html
Oral: 50 to 100 mg every 4 hours as needed.
IV,IM,subcutaneously: 25 to 100 mg every 4 hours as needed.
Continuous IV: 15 to 35 mg/hr.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2886612
Pethidine's stimulant action on the 22-day pregnant rat isolated uterus does not involve receptors sensitive to methysergide and is unlikely to involve the synthesis and release of endogenous prostaglandins. Maximal stimulant response occurred with 40 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 23:23:24 UTC 2023
by
admin
on
Thu Jul 06 23:23:24 UTC 2023
|
Record UNII |
9E338QE28F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02AG03
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-ATC |
N02AB72
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
LIVERTOX |
NBK548764
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
NDF-RT |
N0000175690
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
DEA NO. |
9230
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-ATC |
N02AB52
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
NDF-RT |
N0000175684
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-VATC |
QN02AB72
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-VATC |
QN02AB02
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-ATC |
N02AB02
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-VATC |
QN02AB52
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
||
|
WHO-ATC |
N02AG03
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9023253
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
6754
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
57-42-1
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
100000082223
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
7221
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
411
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
200-329-1
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
PETHIDINE
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
DB00454
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
Meperidine
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
4058
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL607
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
D008614
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
C71632
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
9E338QE28F
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
9E338QE28F
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
3116
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
SUB09738MIG
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
M7186
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
1690
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY | |||
|
6754
Created by
admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||